In a significant leap forward for hematological oncology, ARUP Laboratories has officially launched the CLARISPECT Multiple Myeloma MRD by Spectral Flow Cytometry assay. This clinical-grade diagnostic tool is engineered to provide unprecedented depth in minimal residual disease (MRD) profiling for patients diagnosed with multiple myeloma (MM). By leveraging the precision of spectral flow cytometry, the assay promises to redefine the standard of care for identifying persistent neoplastic cells, offering clinicians a more granular view of disease status than traditional methods.
The Evolution of MRD Assessment in Multiple Myeloma
Minimal residual disease (MRD) testing has become a cornerstone in the management of multiple myeloma. Unlike complete remission, which focuses on the absence of symptoms or detectable disease by standard imaging, MRD assessment measures the presence of microscopic populations of cancer cells that remain after treatment. The significance of this cannot be overstated; the depth of the molecular response is directly correlated with long-term survival outcomes and the likelihood of clinical relapse.
Traditionally, MRD has been assessed through conventional flow cytometry or molecular testing. However, these methods often struggle to detect extremely low-frequency cell populations, potentially leaving patients with "false-negative" results who are actually at high risk of disease progression. The introduction of the CLARISPECT assay aims to bridge this diagnostic gap, providing a more robust mechanism to identify deep molecular responses or early signs of disease resurgence.
How Spectral Flow Cytometry Transforms Diagnostics
At the heart of the CLARISPECT assay is the sophisticated technology of spectral flow cytometry. While traditional flow cytometry relies on individual fluorochromes that emit light in discrete bands, spectral flow cytometry captures the full emission spectrum of every fluorescent tag used. This fundamental shift in data acquisition allows for the simultaneous analysis of dozens of markers with significantly higher signal-to-noise ratios.
For the multiple myeloma assay, ARUP has optimized this technology to assess 18 distinct markers within a single-tube configuration. This design choice is not merely for efficiency; it drastically reduces the required specimen volume, an essential factor for patients who may be frail or who require frequent monitoring.
The assay’s analytical power is quantifiable: it is capable of detecting as few as 14 neoplastic cells within a population of five million analyzed cells with a 95% confidence level. This level of sensitivity is transformative, allowing laboratories to identify disease markers that were previously invisible to conventional screening tools.
Chronology of Innovation at ARUP Laboratories
ARUP Laboratories, a national reference laboratory with over four decades of experience in diagnostic medicine, has long prioritized the integration of advanced technology into clinical workflows.
- Foundation and Growth: Over the past 40 years, ARUP has built a reputation for handling high-complexity cases, specializing in rare diseases and high-volume diagnostic testing.
- Strategic Collaboration (February 2025): The laboratory deepened its commitment to patient-centric diagnostic accessibility by partnering with Tasso. This collaboration focused on operationalizing at-home blood testing services, signaling ARUP’s intent to decentralize diagnostics and integrate clinical research more deeply into the patient’s home environment.
- The Launch of CLARISPECT (July 2026): Following extensive validation phases that utilized ARUP’s massive database of complex clinical cases, the CLARISPECT assay was introduced to the market. This launch represents the culmination of a multi-year effort to refine spectral flow cytometry for high-stakes oncology applications.
- Future Trajectory: ARUP has already signaled that the CLARISPECT Multiple Myeloma MRD assay is merely the first in a broader suite of planned spectral flow cytometry tests, suggesting a long-term roadmap to standardize this technology across various hematologic malignancies.
Insights from Clinical Leadership
The development of this assay reflects a broader strategic push within ARUP to move beyond traditional diagnostic boundaries.
Madhu Menon, head of hematopathology clinical operations at ARUP, highlighted the clinical necessity of this technology. "We are harnessing a technology that’s relatively new in the diagnostic space," Menon stated. "By offering a superior technique with higher sensitivity, we will directly impact a subset of patients who otherwise would not have been identified as MRD-positive. We will be able to detect the reemergence of disease at an earlier timepoint, which will then facilitate more informed decisions at an earlier timepoint."
This sentiment was echoed by Dr. Tracy George, ARUP’s chief scientific officer and president of the innovation business unit. Dr. George emphasized that the laboratory’s unique position—handling a high volume of complex, rare disease cases—was instrumental in the validation process.
"We see large volumes with high complexity cases, including rare diseases. This ensures not only the breadth and depth of our validation, but also the quality of our interpretations," George noted. "We are always pushing the envelope to develop better techniques that improve our ability to diagnose disease. The launch of CLARISPECT demonstrates our commitment to innovation and to patient care."
Implications for Clinical Practice and Patient Outcomes
The implementation of the CLARISPECT assay is expected to have several cascading effects on the treatment landscape for multiple myeloma:
1. Enhanced Risk Stratification
By providing a more accurate assessment of residual disease, oncologists can better categorize patients into risk groups. This allows for the personalization of maintenance therapies—escalating treatment for those who remain MRD-positive or potentially de-escalating for those who have achieved a profound molecular response.
2. Early Detection of Relapse
Because the assay is significantly more sensitive than previous iterations, it serves as an early-warning system. Identifying the reemergence of neoplastic cells months or even years before they manifest as clinical symptoms gives patients a broader window of opportunity for intervention.
3. Specimen Efficiency
For patients undergoing serial monitoring, the reduction in required specimen volume—achieved through the streamlined 18-marker single-tube configuration—minimizes the physical burden of testing. This is particularly relevant in the context of chronic disease management, where repeated blood draws are often required.
4. Setting New Industry Standards
ARUP’s move to normalize spectral flow cytometry in a clinical setting serves as a bellwether for the rest of the industry. As spectral technology becomes more accessible and validated, it is likely to become the new baseline for hematopathology, pushing older, less sensitive methods out of clinical practice.
Conclusion: A New Era in Hematological Diagnostics
The launch of the CLARISPECT Multiple Myeloma MRD assay represents more than just a new product; it reflects a paradigm shift in how we define and detect cancer. By moving toward technologies that offer higher spectral resolution and greater sensitivity, laboratories are empowering physicians to treat multiple myeloma with a precision that was previously unattainable.
As ARUP Laboratories continues to expand its suite of spectral flow cytometry tests, the broader medical community will be watching closely. With the ability to see the "invisible" disease, the hope is that these diagnostic advancements will lead to significantly improved longitudinal outcomes for patients navigating the complexities of multiple myeloma. The future of oncology is increasingly digital, spectral, and, above all, precise.
About the Author
